US · DERM
Journey Medical Corporation
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Scottsdale, AZ 85258
- Website
- journeymedicalcorp.com
Price · as of 2024-12-31
$5.19
Market cap 188.32M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $205.90 | +3,867.24% |
| Intrinsic Value(DCF) | $2.51 | -51.64% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $14.22 | +173.97% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $509.90 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $1.25 | $0.00 | |||
| 2020 | $2.20 | $10.95 | |||
| 2021 | $4.42 | $195.18 | $88.07 | $0.00 | $0.00 |
| 2022 | $1.45 | $64.33 | $126.03 | $0.00 | $0.00 |
| 2023 | $3.45 | $131.74 | $0.77 | $0.06 | $0.00 |
| 2024 | $5.14 | $205.90 | $0.56 | $0.00 | $14.22 |
AI valuation
Our deep-learning model estimates Journey Medical Corporation's (DERM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $205.90
- Current price
- $5.19
- AI upside
- +3,867.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.51
-51.64% upside
Graham-Dodd
—
— upside
Graham Formula
$14.22
+173.97% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DERM | Journey Medical Corporati… | $5.19 | 188.32M | +3,867% | -52% | — | +174% | -7.16 | 5.23 | 1.87 | -13.15 | -2.95 | -8.90 | 62.81% | -24.36% | -26.14% | -72.60% | -75.75% | -18.68% | 1.28 | -5.07 | 1.37 | 0.87 | -0.64 | 24286.00% | -2911.00% | -1015292.00% | -22.97% | -0.26 | -133.63% | 0.00% | 0.00% | 0.00% | -8.07 | -4.58 | 1.97 | -0.14 |
| FENC | Fennec Pharmaceuticals In… | $8.49 | 233.9M | +1,836% | +110,254% | — | — | -430.69 | -31.98 | 3.95 | 37.62 | — | -31.98 | 93.30% | 5.40% | -0.92% | 4.98% | -72.31% | -1.21% | -3.29 | 0.63 | 6.38 | 5.71 | -1.52 | -9733.00% | 12369.00% | -25738.00% | 14.37% | 3.90 | -759.68% | 0.00% | 0.00% | 13.40% | 70.28 | 6.69 | 3.80 | -2.39 |
| HSDT | Solana Company | $1.87 | 75.36M | +7,559% | +13,131% | — | +2,272% | -77.89 | 863.60 | 1758.75 | -66.18 | — | 863.60 | -11.92% | -2673.65% | -2258.08% | -688.88% | 995.92% | -209.04% | 0.01 | -817.82 | 1.58 | 0.80 | 0.08 | -4052.00% | -1925.00% | 575.00% | -1.21% | -5.10 | 791.26% | 0.00% | 0.00% | 0.00% | -65.70 | -82.70 | 1756.68 | 140.75 |
| IVA | Inventiva S.A. | $6.49 | 337.36M | +349% | -81% | — | +2,278% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| MDWD | MediWound Ltd. | $17.30 | 187.92M | +19% | -58% | — | — | -5.58 | 5.41 | 8.34 | -4.71 | -1.84 | 5.43 | 8.81% | -95.85% | -149.46% | -96.33% | 446.97% | -43.19% | 0.22 | -34.55 | 1.97 | 1.85 | 0.08 | 30400.00% | 822.00% | 1753.00% | -11.80% | -0.51 | 458.83% | 0.00% | 0.00% | 0.00% | -6.83 | -6.65 | 6.55 | -1.69 |
| NYXH | Nyxoah S.A. | $4.08 | 152.37M | +571% | +9% | — | — | -4.96 | 2.47 | 61.97 | -3.74 | -29.59 | 4.46 | 65.67% | -1300.80% | -1310.24% | -53.42% | -113.83% | -39.94% | 0.20 | -30.90 | 4.56 | 4.13 | 0.20 | 1677.00% | 398.00% | -79.00% | -19.74% | -2.29 | -107.03% | 0.00% | 0.00% | 0.94% | -3.69 | -3.93 | 48.05 | 1.18 |
| OBIO | Orchestra BioMed Holdings… | $4.38 | 247.32M | +415% | -61% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
| OGI | Organigram Global Inc. | $1.43 | 193.24M | +1,566% | -48% | -16% | — | -11.89 | 0.84 | 1.58 | -18.57 | — | 1.06 | 3.67% | -34.07% | -9.55% | -7.56% | -15.33% | -5.10% | 0.03 | — | 2.26 | 0.74 | 1.32 | -7083.00% | 1642.00% | 102705.00% | -5.61% | -0.03 | -6.21% | 0.00% | 0.00% | 0.00% | -4.32 | -16.59 | 1.47 | -0.39 |
| OSUR | OraSure Technologies, Inc… | $3.15 | 230.38M | +1,022% | -63% | — | +744% | -3164.74 | 0.64 | 1.89 | -3.83 | -1210.05 | 0.64 | 41.90% | -59.23% | -59.76% | -0.02% | -27.37% | -0.02% | 0.00 | — | 6.58 | 0.01 | 0.00 | 26154.00% | -3810.00% | -10023.00% | -0.02% | 0.00 | -0.02% | 0.00% | 0.00% | 6.91% | -3.19 | -4083.36 | 1.89 | 2.48 |
| RNAC | Cartesian Therapeutics, I… | $7.59 | 197.37M | +525% | +8% | — | — | -6.16 | -70.08 | 12.25 | -3.66 | — | -2.32 | 100.00% | -112.81% | -198.97% | 34.64% | 12.34% | -20.92% | -2.06 | — | 9.43 | 9.29 | 2.61 | -9339.00% | 4964.00% | -3621.00% | -6.87% | -1.03 | 9.21% | 0.00% | 0.00% | 27.83% | -6.33 | -8.48 | 7.14 | -1.29 |
| SXTC | China SXT Pharmaceuticals… | $2.28 | 1.95M | +6,431% | +5,777% | — | +346% | -35.58 | 7.61 | 67.52 | -39.03 | -27.55 | 7.62 | 21.11% | -153.97% | -189.77% | -22.50% | -189.29% | -14.75% | 0.06 | -4.14 | 3.54 | 3.33 | 6.65 | 12913.00% | -973.00% | 2130.00% | -2.00% | -0.39 | -165.76% | 0.00% | 0.00% | 6.54% | -37.47 | -42.78 | 57.69 | 10.04 |
About Journey Medical Corporation
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
- CEO
- Claude Maraoui
- Employees
- 41
- Beta
- 0.82
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.51 ÷ $5.19) − 1 = -51.64% (DCF, example).